REGN - Regeneron Pharmaceuticals, Inc. Stock Price and Quote

REGN | Regeneron Pharmaceuticals, Inc. | [NASD]

Index	NDX, S&P 500	P/E	19.80	EPS (ttm)	36.80	Insider Own	0.50%	Shs Outstand	107.10M	Perf Week	-3.05%
Market Cap	79.93B	Forward P/E	16.79	EPS next Y	43.38	Insider Trans	-8.55%	Shs Float	104.32M	Perf Month	-9.13%
Income	4.18B	PEG	7.07	EPS next Q	10.19	Inst Own	89.50%	Short Float / Ratio	1.16% / 2.11	Perf Quarter	-4.18%
Sales	12.37B	P/S	6.46	EPS this Y	-46.90%	Inst Trans	-0.34%	Short Interest	1.21M	Perf Half Y	-1.04%
Book/sh	219.38	P/B	3.32	EPS next Y	4.32%	ROA	14.70%	Target Price	889.32	Perf Year	6.61%
Cash/sh	81.67	P/C	8.92	EPS next 5Y	2.80%	ROE	19.00%	52W Range	538.01 - 837.55	Perf YTD	0.99%
Dividend	-	P/FCF	31.63	EPS past 5Y	23.80%	ROI	16.60%	52W High	-13.01%	Beta	0.24
Dividend %	-	Quick Ratio	4.70	Sales past 5Y	15.70%	Gross Margin	87.00%	52W Low	35.42%	ATR	14.40
Employees	11851	Current Ratio	5.50	Sales Q/Q	6.60%	Oper. Margin	35.80%	RSI (14)	34.61	Volatility	1.52% 1.84%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-16.70%	Profit Margin	33.80%	Rel Volume	0.86	Prev Close	725.05
Shortable	Yes	LT Debt/Eq	0.11	Earnings	May 04 BMO	Payout	0.00%	Avg Volume	575.84K	Price	728.60
Recom	2.10	SMA20	-3.55%	SMA50	-7.23%	SMA200	-1.04%	Volume	497,087	Change	0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976
Mar-24-23	Upgrade	Jefferies	Hold → Buy	$675 → $925
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform	$775 → $875
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight	$850
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line	$760
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$625 → $851
Sep-09-22	Upgrade	Jefferies	Underperform → Hold	$536 → $675
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$630
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$625
Jun-06-22	Initiated	Jefferies	Underperform	$536
May-23-22	Initiated	SVB Leerink	Outperform	$738
Jan-05-22	Downgrade	BofA Securities	Neutral → Underperform	$675 → $575
Jan-03-22	Upgrade	Bernstein	Mkt Perform → Outperform	$660
Dec-15-21	Downgrade	Bernstein	Outperform → Mkt Perform	$660
Dec-09-21	Resumed	Wells Fargo	Overweight	$750
Dec-07-21	Resumed	Cowen	Market Perform	$625
Dec-06-21	Initiated	Goldman	Buy	$824
Nov-19-21	Resumed	BMO Capital Markets	Outperform	$780

Show Previous Ratings

May-26-23 11:04AM	Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study (Zacks)
May-25-23 05:05PM	Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma (GlobeNewswire)
05:00PM	Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations (GlobeNewswire)
04:03AM	14 Best Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
May-22-23 01:50PM	Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained (Benzinga)
02:18PM	Loading…
May-21-23 02:18PM	Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine (GlobeNewswire)
May-20-23 07:01AM	Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their solid 158% return over the last five years (Simply Wall St.)
May-19-23 03:32PM	High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 (PR Newswire)
01:42PM	Regeneron (REGN) Faces Challenges as Eylea Sales Decline (Zacks)
12:54PM	High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 (GlobeNewswire)
May-18-23 04:01PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
01:58PM	Sanofi Wins Supreme Court Patent Dispute With Amgen (The Wall Street Journal)
11:45AM	Regeneron Applauds Supreme Courts Unanimous Opinion Striking Down Amgens PCSK9 Patent Claims and Supporting Scientific Innovation (GlobeNewswire)
10:20AM	UPDATE 3-U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents (Reuters)
May-17-23 12:01AM	Regeneron boss backs attempt to block $28bn Amgen acquisition (Financial Times)
09:00AM	Loading…
May-16-23 09:00AM	Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? (Simply Wall St.)
May-15-23 03:59PM	CEO Pay Packages Fell Sharply in 2022, the First Decline in a Decade (The Wall Street Journal)
May-10-23 09:53AM	2 Cathie Wood Stocks That Can Get You Through Any Recession (Motley Fool)
May-09-23 11:33PM	Q1 2023 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
04:09PM	15 Biggest Immunotherapy Companies in the World (Insider Monkey)
02:59PM	Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2023 Earnings Call Transcript (Insider Monkey)
10:00AM	Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 29% Discount? (Simply Wall St.)
May-05-23 05:17PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
09:00AM	Regeneron Pharmaceuticals Insider Lowered Holding By 26% During Last Year \ (Simply Wall St.)
May-04-23 11:18PM	Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.14%
04:07PM	Regeneron Sacrifices A Breakout As Competition Hammers At Its Biggest Moneymaker (Investor's Business Daily)
03:50PM	Why Regeneron Pharmaceuticals Shares Are Trading Lower Today (Benzinga)
01:23PM	Why Regeneron Pharmaceuticals Stock Is Tanking Today (Motley Fool)
12:03PM	Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Regeneron (REGN) Q1 Earnings (Zacks)
08:50AM	Loading…
08:50AM	Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker (Investor's Business Daily)
07:55AM	Regeneron (REGN) Q1 Earnings and Revenues Top Estimates (Zacks)
06:39AM	Regeneron's Eylea drug sales hit by competition from 'new kid in town' (Reuters)
06:30AM	Regeneron Reports First Quarter 2023 Financial and Operating Results (GlobeNewswire)
May-03-23 11:46AM	Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More (Zacks)
08:36AM	Why Earnings Season Could Be Great for Regeneron (REGN) (Zacks)
May-02-23 11:40AM	LGND vs. REGN: Which Stock Is the Better Value Option? (Zacks)
09:00AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
07:00AM	Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research (GlobeNewswire)
May-01-23 08:02AM	Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings? (Zacks)
Apr-28-23 01:12PM	Stock Charts Strategy, May 1-5: Fed Policy, April Payrolls, Apple Earnings (Investor's Business Daily)
Apr-27-23 06:15PM	Regeneron (REGN) Gains But Lags Market: What You Should Know (Zacks)
01:52PM	Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says (Benzinga)
10:02AM	Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-26-23 04:05PM	Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimers Disease and Cerebral Amyloid Angiopathy (GlobeNewswire)
04:05PM	Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimers Disease and Cerebral Amyloid Angiopathy (Business Wire)
Apr-24-23 01:34PM	Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea (Benzinga)
08:38AM	4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates (Zacks)
08:00AM	Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet? (Simply Wall St.)
Apr-21-23 06:15PM	Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know (Zacks)
09:00AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Apr-20-23 01:07PM	The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio (InvestorPlace)
Apr-18-23 10:00AM	Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their splendid 159% return over the last five years (Simply Wall St.)
Apr-17-23 09:50AM	Regeneron Set to Reach New Heights: $1,000 in Sight? (TheStreet.com)
07:30AM	Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary (GlobeNewswire)
07:00AM	Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases (GlobeNewswire)
Apr-14-23 10:00AM	Are Strong Financial Prospects The Force That Is Driving The Momentum In Regeneron Pharmaceuticals, Inc.'s NASDAQ:REGN) Stock? (Simply Wall St.)
Apr-11-23 04:00PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
10:51AM	12 Best Covid Treatment Stocks to Buy Today (Insider Monkey)
Apr-09-23 09:30AM	Investing $1,000 In These 2 Top Stocks Would Be a Great Move (Motley Fool)
Apr-08-23 07:00AM	A Look At The Intrinsic Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) (Simply Wall St.)
Apr-07-23 12:10PM	Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-06-23 05:39AM	2 Top Growth Stocks That Could Soar This Spring (Motley Fool)
Apr-04-23 09:00AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
07:00AM	One Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider reduced their stake by 26% in the previous year (Simply Wall St.)
Apr-03-23 04:00PM	Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023 (GlobeNewswire)
Mar-31-23 10:15PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
06:15PM	Regeneron (REGN) Gains But Lags Market: What You Should Know (Zacks)
Mar-29-23 11:24AM	Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback (Zacks)
07:43AM	Regeneron Shares Rally on Heavy Demand and Strong Fundamentals (FX Empire)
07:00AM	Technical Assessment: Bearish in the Intermediate-Term (Argus Research)
07:00AM	Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) (GlobeNewswire)
Mar-28-23 03:25PM	Unity (UNX) Down on Disappointing Results From Wet AMD Study (Zacks)
07:30AM	Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases (Business Wire)
07:30AM	Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases (GlobeNewswire)
Mar-27-23 06:51PM	Amgen-Sanofi patent case divides makers of antibody drugs (Reuters)
01:28PM	UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug (Benzinga)
11:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
10:35AM	UPDATE 3-U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents (Reuters)
07:41AM	The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly (Zacks)
06:00AM	Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court (Reuters)
Mar-26-23 08:45AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Mar-25-23 12:54PM	Regeneron and Sanofi Look for Billions From COPD Drug (The Wall Street Journal)
Mar-24-23 02:29PM	Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7% (Zacks)
02:17PM	Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough (Investor's Business Daily)
12:02PM	Wall Street Has High Hopes for These 2 Nasdaq Stocks (Motley Fool)
09:17AM	Regenerons Asthma Drug Results Were Stellar. Analyst Sees a Sales Bonanza. (Barrons.com)
09:04AM	Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL (Zacks)
08:00AM	ETFs in Focus on Sanofi and Regeneron's COPD Drug Data (Zacks)
07:47AM	5 analyst picks of the day: Nike upped on Q3 beat \| Pro Recap (Investing.com)
04:07AM	First Republic, Deutsche Bank, Chevon, Block fall premarket; Regeneron rises (Investing.com)
03:04AM	Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock? (Zacks)
Mar-23-23 04:40PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research) +6.77%
04:02PM	Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars (Investor's Business Daily)
01:39PM	Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study (Zacks)
12:08PM	Why Shares of Regeneron Are Rising Thursday (Motley Fool)
10:00AM	Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment? (Simply Wall St.)
09:20AM	Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today (Benzinga)
09:03AM	Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' (Investor's Business Daily)
08:14AM	Sanofi, Regenerons Drug Succeeds in High-Stakes Lung Trial (Bloomberg)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RYAN ARTHUR F	Director	May 01	Sale	805.33	100	80,533	18,947	May 03 04:01 PM
BROWN MICHAEL S	Director	Apr 21	Option Exercise	520.01	3,070	1,596,431	4,317	Apr 24 04:05 PM
BROWN MICHAEL S	Director	Apr 21	Sale	798.42	3,070	2,451,149	1,247	Apr 24 04:05 PM
McCourt Marion	EVP Commercial	Apr 03	Option Exercise	372.46	1,100	409,706	21,903	Apr 05 04:00 PM
McCourt Marion	EVP Commercial	Apr 03	Sale	818.80	1,100	900,680	20,803	Apr 05 04:00 PM
RYAN ARTHUR F	Director	Apr 03	Sale	819.31	100	81,931	19,047	Apr 05 04:01 PM
Landry Robert E	EVP Finance CFO	Mar 28	Sale	823.47	1,007	829,233	31,922	Mar 29 04:07 PM
Landry Robert E	EVP Finance CFO	Mar 27	Option Exercise	379.60	3,800	1,442,476	35,316	Mar 29 04:07 PM
Landry Robert E	EVP Finance CFO	Mar 27	Sale	821.70	183	150,372	32,929	Mar 29 04:07 PM
Bassler Bonnie L	Director	Mar 24	Option Exercise	380.95	1,240	472,378	2,487	Mar 27 04:43 PM
Bassler Bonnie L	Director	Mar 24	Sale	818.00	1,240	1,014,320	1,247	Mar 27 04:43 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Mar 23	Option Exercise	270.43	10,000	2,704,300	34,213	Mar 27 04:39 PM
YANCOPOULOS GEORGE	President and Chief Scientific	Mar 23	Sale	804.26	3,656	2,940,374	196,848	Mar 27 04:41 PM
Fenimore Christopher R.	SVP Controller	Mar 23	Sale	806.47	2,192	1,767,782	18,409	Mar 27 04:37 PM
McCourt Marion	EVP Commercial	Mar 01	Option Exercise	372.46	1,100	409,706	21,903	Mar 03 04:03 PM
McCourt Marion	EVP Commercial	Mar 01	Sale	759.89	1,100	835,879	20,803	Mar 03 04:03 PM
RYAN ARTHUR F	Director	Mar 01	Sale	762.50	100	76,250	19,147	Mar 03 04:03 PM
VAGELOS P ROY	Director	Feb 22	Option Exercise	270.43	42,500	11,493,275	366,583	Feb 24 04:07 PM
McCourt Marion	EVP Commercial	Feb 07	Option Exercise	372.46	1,000	372,460	23,079	Feb 08 04:14 PM
McCourt Marion	EVP Commercial	Feb 07	Sale	769.04	1,000	769,040	22,079	Feb 08 04:14 PM
GOLDSTEIN JOSEPH L	Director	Feb 06	Option Exercise	482.68	3,613	1,743,923	9,860	Feb 08 04:16 PM
BROWN MICHAEL S	Director	Feb 06	Option Exercise	520.01	3,071	1,596,951	4,318	Feb 08 04:15 PM
YANCOPOULOS GEORGE	President and Chief Scientific	Feb 06	Sale	800.08	13,189	10,552,255	200,504	Feb 08 04:15 PM
GOLDSTEIN JOSEPH L	Director	Feb 06	Sale	800.00	3,613	2,890,400	6,247	Feb 08 04:16 PM
BROWN MICHAEL S	Director	Feb 06	Sale	798.00	3,071	2,450,658	1,247	Feb 08 04:15 PM
Landry Robert E	EVP Finance CFO	Feb 06	Sale	788.88	752	593,238	32,105	Feb 07 04:09 PM
BROWN MICHAEL S	Director	Feb 06	Sale	797.00	500	398,500	6,162	Feb 08 04:15 PM
Fenimore Christopher R.	SVP Controller	Feb 03	Option Exercise	270.43	5,000	1,352,150	23,581	Feb 07 04:10 PM
Landry Robert E	EVP Finance CFO	Feb 03	Option Exercise	381.92	3,000	1,145,760	35,105	Feb 07 04:09 PM
Bassler Bonnie L	Director	Feb 03	Option Exercise	380.95	1,021	388,950	2,268	Feb 07 04:09 PM
Bassler Bonnie L	Director	Feb 03	Sale	779.00	1,021	795,359	1,247	Feb 07 04:09 PM
Landry Robert E	EVP Finance CFO	Feb 03	Sale	764.50	739	564,966	32,105	Feb 07 04:09 PM
McCourt Marion	EVP Commercial	Feb 01	Option Exercise	372.46	1,100	409,706	23,179	Feb 03 04:13 PM
McCourt Marion	EVP Commercial	Feb 01	Sale	752.19	1,100	827,409	22,079	Feb 03 04:13 PM
RYAN ARTHUR F	Director	Feb 01	Sale	756.13	100	75,613	19,247	Feb 03 04:15 PM
BROWN MICHAEL S	Director	Jan 27	Option Exercise	520.01	1	520	1,248	Jan 30 04:11 PM
BROWN MICHAEL S	Director	Jan 27	Sale	747.00	1	747	1,247	Jan 30 04:11 PM
BROWN MICHAEL S	Director	Jan 06	Option Exercise	520.01	3,070	1,596,431	4,317	Jan 10 04:03 PM
BROWN MICHAEL S	Director	Jan 06	Sale	747.14	3,070	2,293,720	1,247	Jan 10 04:03 PM
McCourt Marion	EVP Commercial	Jan 03	Option Exercise	372.46	1,100	409,706	23,179	Jan 05 04:22 PM
McCourt Marion	EVP Commercial	Jan 03	Sale	721.86	1,100	794,046	22,079	Jan 05 04:22 PM
RYAN ARTHUR F	Director	Jan 03	Sale	726.29	100	72,629	19,182	Jan 05 04:37 PM
COLES N ANTHONY	Director	Dec 28	Option Exercise	442.24	5,758	2,546,410	6,851	Dec 30 04:10 PM
COLES N ANTHONY	Director	Dec 28	Sale	714.11	5,758	4,111,822	1,093	Dec 30 04:10 PM
McCourt Marion	EVP Commercial	Dec 12	Sale	730.17	264	192,765	19,106	Dec 13 04:13 PM
Landry Robert E	EVP Finance CFO	Dec 08	Option Exercise	381.92	3,000	1,145,760	31,744	Dec 12 04:34 PM
Bassler Bonnie L	Director	Dec 08	Option Exercise	380.95	218	83,047	1,300	Dec 12 04:35 PM
Bassler Bonnie L	Director	Dec 08	Sale	779.00	218	169,822	1,082	Dec 12 04:35 PM
Landry Robert E	EVP Finance CFO	Dec 02	Sale	756.66	610	461,564	28,744	Dec 02 04:05 PM
Landry Robert E	EVP Finance CFO	Dec 01	Option Exercise	381.92	2,500	954,800	31,244	Dec 02 04:05 PM
McCourt Marion	EVP Commercial	Dec 01	Option Exercise	372.46	1,100	409,706	20,744	Dec 02 04:06 PM
McCourt Marion	EVP Commercial	Dec 01	Sale	756.19	1,100	831,809	19,644	Dec 02 04:06 PM
RYAN ARTHUR F	Director	Dec 01	Sale	758.17	100	75,817	19,282	Dec 02 04:07 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Nov 23	Sale	740.75	11,972	8,868,260	30,578	Nov 25 01:07 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Nov 22	Option Exercise	378.98	50,000	18,949,000	80,578	Nov 25 01:07 PM
MURPHY ANDREW J	EVP Research	Nov 15	Sale	727.81	3,720	2,707,467	57,110	Nov 16 04:01 PM
MURPHY ANDREW J	EVP Research	Nov 14	Option Exercise	179.13	10,000	1,791,300	67,110	Nov 16 04:01 PM
BROWN MICHAEL S	Director	Nov 08	Option Exercise	416.62	3,995	1,664,397	3,513	Nov 10 04:00 PM
BROWN MICHAEL S	Director	Nov 08	Sale	755.18	3,995	3,016,946	1,082	Nov 10 04:00 PM
BROWN MICHAEL S	Director	Nov 08	Sale	748.49	500	374,245	6,662	Nov 10 04:00 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Nov 07	Sale	745.40	7,886	5,878,263	30,578	Nov 08 04:00 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Nov 04	Option Exercise	381.92	34,000	12,985,280	64,578	Nov 08 04:00 PM
McCourt Marion	EVP Commercial	Nov 04	Option Exercise	372.46	1,000	372,460	20,644	Nov 07 04:05 PM
McCourt Marion	EVP Commercial	Nov 04	Sale	727.82	1,000	727,820	19,644	Nov 07 04:05 PM
McCourt Marion	EVP Commercial	Nov 01	Option Exercise	372.46	1,100	409,706	20,744	Nov 02 04:03 PM
McCourt Marion	EVP Commercial	Nov 01	Sale	750.00	1,100	825,000	19,644	Nov 02 04:03 PM
Landry Robert E	EVP Finance CFO	Nov 01	Sale	758.06	482	365,386	28,744	Nov 02 04:04 PM
RYAN ARTHUR F	Director	Nov 01	Sale	755.89	100	75,589	19,382	Nov 03 04:03 PM
Landry Robert E	EVP Finance CFO	Oct 31	Option Exercise	381.92	2,000	763,840	30,744	Nov 02 04:04 PM
Landry Robert E	EVP Finance CFO	Oct 17	Sale	739.50	358	264,741	28,744	Oct 18 04:06 PM
Landry Robert E	EVP Finance CFO	Oct 14	Option Exercise	381.92	1,500	572,880	30,244	Oct 18 04:06 PM
Fenimore Christopher R.	SVP Controller	Oct 05	Sale	749.00	1,844	1,381,156	16,425	Oct 07 04:03 PM
Tessier-Lavigne Marc	Director	Oct 03	Option Exercise	413.33	3,612	1,492,948	5,881	Oct 03 04:05 PM
McCourt Marion	EVP Commercial	Oct 03	Option Exercise	359.04	1,100	394,941	20,244	Oct 05 04:11 PM
Tessier-Lavigne Marc	Director	Oct 03	Sale	718.00	3,612	2,593,416	2,269	Oct 03 04:05 PM
Fenimore Christopher R.	SVP Controller	Oct 03	Sale	724.00	3,346	2,422,504	18,269	Oct 05 04:10 PM
McCourt Marion	EVP Commercial	Oct 03	Sale	705.39	1,100	775,929	19,644	Oct 05 04:11 PM
RYAN ARTHUR F	Director	Oct 03	Sale	726.54	100	72,654	19,482	Oct 05 04:10 PM
Tessier-Lavigne Marc	Director	Sep 30	Option Exercise	413.33	3,428	1,416,895	5,697	Oct 03 04:05 PM
Tessier-Lavigne Marc	Director	Sep 30	Sale	698.00	3,428	2,392,744	2,269	Oct 03 04:05 PM
Tessier-Lavigne Marc	Director	Sep 29	Option Exercise	413.33	3,798	1,569,827	6,067	Oct 03 04:05 PM
Tessier-Lavigne Marc	Director	Sep 29	Sale	691.07	3,798	2,624,684	2,269	Oct 03 04:05 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Sep 12	Sale	716.38	4,696	3,364,111	30,578	Sep 13 04:04 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Sep 09	Option Exercise	555.67	40,000	22,226,800	70,578	Sep 13 04:04 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Sep 09	Option Exercise	270.43	30,000	8,112,900	41,580	Sep 12 04:30 PM
Bassler Bonnie L	Director	Sep 09	Option Exercise	376.69	609	229,404	1,691	Sep 12 04:31 PM
Bassler Bonnie L	Director	Sep 09	Sale	741.00	609	451,269	1,082	Sep 12 04:31 PM
Bassler Bonnie L	Director	Sep 08	Option Exercise	391.92	2,558	1,002,531	2,361	Sep 12 04:31 PM
Bassler Bonnie L	Director	Sep 08	Sale	696.00	2,558	1,780,355	1,082	Sep 12 04:31 PM
COLES N ANTHONY	Director	Sep 06	Option Exercise	372.40	6,000	2,234,428	6,793	Sep 08 04:06 PM
COLES N ANTHONY	Director	Sep 06	Sale	581.28	6,000	3,487,657	1,093	Sep 08 04:06 PM
RYAN ARTHUR F	Director	Sep 06	Sale	582.37	100	58,237	19,582	Sep 08 04:07 PM
McCourt Marion	EVP Commercial	Sep 01	Option Exercise	342.93	1,100	377,223	20,744	Sep 02 04:07 PM
McCourt Marion	EVP Commercial	Sep 01	Sale	577.62	1,100	635,382	19,644	Sep 02 04:07 PM
MURPHY ANDREW J	EVP Research	Aug 16	Sale	645.49	3,513	2,267,600	58,470	Aug 17 04:04 PM
MURPHY ANDREW J	EVP Research	Aug 15	Option Exercise	179.13	10,000	1,791,300	68,470	Aug 17 04:04 PM
POON CHRISTINE A	Director	Aug 09	Option Exercise	177.82	15,000	2,667,300	16,872	Aug 11 04:09 PM
POON CHRISTINE A	Director	Aug 09	Sale	620.91	15,000	9,313,599	1,872	Aug 11 04:09 PM
STAHL NEIL	EVP Research and Development	Aug 05	Sale	612.61	23,782	14,569,134	52,795	Aug 08 04:11 PM
STAHL NEIL	EVP Research and Development	Aug 04	Option Exercise	270.43	95,000	25,690,850	147,795	Aug 08 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience